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Minimal information about an immuno-peptidomics experiment (MIAIPE) is an initiative of the members of the Human
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1. Introduction
The immunopeptidome is the ensemble of peptides presented
by major histocompatibility complex (MHC) molecules to T cells
and it plays a key role in mediating speciﬁc elimination of dis-
eased or abnormal cells by the immune system. MHC class I
molecules are ubiquitously expressed on almost all cells and they
present their peptide ligands to CD8+ T cells, while MHC class
II molecules are mainly expressed on immune cells that func-
tion as professional antigen presenting cells that present pep-
tides to CD4+ T cells. Highly specialized cellular machineries
process intracellular and extracellular proteins into short pep-
tide fragments, of which some are further loaded on the MHC
molecules.[1] The presented peptides are mostly derived from the
degradation of the normal cellular proteins, yet during patholo-
gies, some may also be derived from disease-related antigens,
such as tumor-associated antigens and pathogens. Therefore, the
comprehensive knowledge of the MHC bound peptide (pMHC)
repertoire accessible to patrolling T cells is an excellent basis
for designing innovative therapeutics against cancer, autoimmu-
nity, and pathogenic infections. Currently, nanoscale liquid chro-
matography coupled to tandemmass spectrometry (LC-MS/MS)-
based immunopeptidomics is the prime methodology to com-
prehensively interrogate the repertoire of pMHC presented in
vivo.[2] Given the rising number of research laboratories perform-
ing large-scale immunopeptidomics and the growing interest in
detecting clinically relevant peptides by LC-MS/MS, comprehen-
sive data of naturally presented MHC class I and class II pep-
tidomes from thousands of donors and MHC allotypes will be
acquired in the coming years.[3] We foresee that, as is happening
already in other proteomics-based workﬂows, extensive reporting
of experimental procedures and deposition of data in dedicated
repositories will facilitate the reuse of the data and consequently
will enhance the general value of the scientiﬁc work.
In 2015, the Human Immuno-Peptidome Project (HIPP) was
created as a new initiative under the umbrella of the Hu-
man Proteome Organization (HUPO; https://hupo.org/Human-
Immuno-Peptidome-Project/) to further accelerate research
toward comprehensive and reproducible analysis of immunopep-
tidomes. HUPO-HIPP has the long-term goal of increasing
the impact of immunopeptidomics in biomedical research by
enhancing the accessibility of immunopeptidomics data, as well
as experimental and computational techniques, to the whole sci-
entiﬁc community. During the ﬁrst international workshop of
the HUPO-HIPP initiative, leaders in the immunopeptidomics
ﬁeld acknowledged the importance of drafting the minimal in-
formation about an immuno-peptidomics experiment (MIAIPE)
guidelines as a community eﬀort to ensure transparency and
reproducibility in published data.[4] To this end, three working
groups comprised of leading experts in diﬀerent aspects of im-
munopeptidomics have drafted the guidelines, which describe
key information about: 1) sample preparation and the biochem-
ical isolation of pMHC from cells or tissues, 2) LC-MS/MS
parameters, and 3) informatics and statistics. Importantly, the
main principle of the guidelines is not to enforce any particu-
lar experimental design but rather to ensure that published MS-
based immunopeptidomics studies provide essential informa-
tion to the readers to 1) explain the experimental data, 2) assess
the reliability of the results and avoid misinterpretation,
and 3) support the consistent reuse of the data in the
future.
The analysis of immunopeptidomes using LC-MS/MS tech-
nologies is a relatively complex process. Caron et al. have re-
viewed the three main data acquisition concepts in MS that
have been applied in immunopeptidomics,[2] commonly used
in other proteomics MS workﬂows. These include: 1) data-
dependent analysis (DDA) which is the widely used strategy
for so-called “discovery experiments” where the researcher is
interested in proﬁling the repertoire of pMHC from a given
sample[5,6]; 2) selected reaction monitoring (SRM), also referred
to as multiple reaction monitoring (MRM), targeted analyses
whereby ion signatures from both the peptide precursor and
its fragmentation product ions are monitored, and the area un-
der the curve or peak height can be used for quantiﬁcation
purposes; this method ensures a higher degree of selectivity
than a DDA experiment, but at the expense of the experimen-
tal depth and throughput[7]; and 3) data independent analysis
(DIA) strategies, where all peptides within a deﬁned mass-to-
charge (m/z) window are subjected to fragmentation and record-
ing of their combined MS/MS spectra; the precursor isolation
window sequentially marches up the full m/z range and this
analysis is repeated again and again during chromatographic
elution.[8] This less mature technique promises excellent per-
formance for both discovery and quantitative analyses, espe-
cially with regard to reproducibility and more accurate label-free
quantiﬁcation.[9]
Most of immunopeptidomics studies are discovery oriented;
therefore, the main focus of the current MIAIPE guidelines
is on reporting and interpreting DDA MS data. Furthermore,
as the immunopeptidomics MS approach and the supportive
bioinformatics tools are those commonly used in general pro-
teomics techniques, several parts of the guidelines below over-
lap with the existing general MIAPE guidelines,[10–13] developed
under the umbrella of the HUPO Proteomics Standards Initia-
tive, and the Paris Guidelines on reporting and deposition of pro-
teomics datasets (http://www.mcponline.org/site/misc/ParisRe-
port_Final.xhtml). For the sake of completeness and clarity, we
have included overlapping content and elaborate further on the
immunopeptidomics speciﬁc aspects.
2. Preparation of pMHC Samples
The ﬁrst methods used for the isolation of pMHC have been de-
scribed by the labs of Sette for class II[14] and Rammensee for
class I.[15] Since these pioneering studies, pMHC have been iso-
lated biochemically from a wide range of biological samples for
fundamental research,[16] as well as for translational and clinical
research.[17] Three accepted methods for the isolation of MHC
class I or class II peptides have emerged in the last decades:
1) mild acid elution, where the cell surface MHC class I but
not class II complexes are denatured at approximately pH 3.3,
therefore releasing the MHC class I peptides while leaving the
cells intact[18]; 2) immunoaﬃnity puriﬁcation of the endoge-
nous pMHC from cells, tissues, and body ﬂuids using MHC-
speciﬁc monoclonal antibodies bound to solid support[19]; and
3) immunoaﬃnity puriﬁcation of transfected recombinant sol-
uble or membrane-anchored MHC molecules using anti-MHC
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antibodies or antibodies against aﬃnity tags.[20] Stable isotope la-
beling of the cellular proteins has been used in order to follow
their synthesis, degradation dynamics, and the MHC presenta-
tion of their derived peptides and to assess the degree to which
pMHC is derived from defective ribosome products[21] and has
been applied for the identiﬁcation of pathogen-derived pMHC.[22]
A comprehensive description of such advanced experimental ap-
proaches is required, and in this section, we cover aspects related
to the extraction of pMHC from the biological samples and their
preparation and storage prior to the LC-MS/MS characterization.
2.1. Sample Preparation
2.1.1. Sample Metadata
Indicate the sample name or identiﬁer, speciﬁcally, host (use
NCBI taxonomy terms or identiﬁers), tissue of origin, and cell
type (include catalogue number, if commercially available). In-
dicate the MHC allotypes according to the MHC Restriction
Ontology (MRO) terminology/identiﬁers available, for exam-
ple, via the Ontology Lookup Service (https://www.ebi.ac.uk/
ols/ontologies/mro), for example, HLA- A*02:01. Indicate the
method used for typingMHCalleles (e.g., PCR-based and exome-
capture sequencing data). In case of transgenic modiﬁed cells,
describe the vector and the recombinant MHC molecule. Indi-
cate if nonhost antigens have been externally supplied or presum-
ably expressed in the samples. Indicate if and how chemical or
metabolic labeling was applied, if the sample has been fraction-
ated and how, and if exogenous standards have been added to the
sample. Indicate amount of starting material per sample (e.g.,
number of cells, amount of tissue, volume of plasma, and cul-
tured cell growth medium) and indicate patient consent if appli-
cable. The number of technical and biological replicates should
be indicated for each experiment.
2.1.2. Reagents and Equipment
Indicate buﬀer compositions, concentration, pH, and tempera-
ture (e.g., detergents, salts, protease inhibitors). Indicate detailed
information and suppliers of plasticware and chromatography
materials (e.g., ultraﬁltration units, C18 tips, and columns).
2.1.3. . Cell Culture Conditions
Indicate the media and serum used for the cell culture. Indi-
cate if speciﬁc additives were added, including antibiotics used
for the selection of transfected cells. Indicate if stable isotope la-
beled amino acids were used, their concentration, supplier, and
isotopes used for their labeling.
2.1.4. Mild Acid Elution Method
Describe washing of cells prior to the acid elution. Indicate
the exact buﬀer composition, volume, concentration, pH and
temperature, and duration at which one performed the acid elu-
tion per sample. Describe how the peptides-containing samples
were cleared (e.g., ﬁltration, centrifugal force, temperature, and
duration).
2.1.5. Antibody Coupling to Resin for IP
Indicate the name of antibody used for the aﬃnity puriﬁcation
and, in case the antibodies are described for the ﬁrst time, add
information about isotype and origin and the MHC allele speci-
ﬁcity. Provide information on the type of coupling resin (manu-
facturer information) and coupling chemistry/biochemistry em-
ployed. Indicate the ratio of antibody to resin, buﬀer composition,
temperature, and duration of coupling and quenching reactions.
Indicate the cartridge or column device used for the cross linking
procedures.
2.1.6. IP Method
Describe the storage and preparation of cells, tissues, or body ﬂu-
ids prior to the IP. If MHC complexes have been isolated from
tissues, include disruption conditions (e.g., mechanical or enzy-
matic), temperature and duration, and if any washing steps were
involved. If isolated from body ﬂuids, include the addition of
anticoagulation factors and protease inhibitors, centrifugations,
etc.
Indicate the lysis buﬀer volume used per sample, incubation
time and temperature, agitation or physico-mechanical process.
Describe how the lysates were cleared (e.g., ﬁltration, centrifugal
force, temperature, and duration). Describe the solutions used
for conditioning and washing the resin prior to the IP. Indicate
the format of the IP device (type of column or tube), how cell
lysates were introduced into the IP device and the duration of the
IP process. Indicate the ratio of lysate per IP resin, if agitation
was used during incubation or if peristaltic ﬂow or gravity forces
were used to maintain the ﬂow. Describe composition, volume,
and administration of all washes and elution steps.
2.1.7. Extraction and Separation of the pMHC
Describe the cleanup approach taken to separate the peptides
from cell debris and other contaminating proteins. If molecular
weight cutoﬀ (MWCO) ﬁlters or C18 cartridges were used, indi-
cate the manufacturer and catalog name. Include conditioning
and washing steps, amount of the sample loaded, centrifugation
force, temperature and duration, and details about the buﬀers
and volume used to elute the peptides.
If peptide samples were fractionated, enriched for modiﬁca-
tion (e.g., phosphopeptides) or chemically labeled for quantita-
tive analyses, describe the procedures. Provide information on
the column dimensions, stationary phase, buﬀers, column tem-
perature, ﬂow rate, and number of fractions collected and com-
bined.
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2.1.8. Concentration and Storage of Samples
Indicate if eluted peptide solutions were reduced in volume by
vacuum centrifugation or lyophilization, and the conditions of
storage.
2.1.9. Preparation of Sample Prior to LC-MS/MS
Describe the solvents used for resuspending the peptides prior to
MS and the volume and percentage of injected sample. Specify
the number of LC-MS/MS runs per sample (injection replicates).
3. LC-MS/MS-Based Detection of
Immunopeptidomes
The Rammensee lab reported the ﬁrst application of mass
spectrometry and Edman degradation for the identiﬁcations of
pMHC,[23] while in 1992, Hunt et al.[24] published the ﬁrst LC-
MS/MS approach for the identiﬁcation of eluted pMHC. Their
basic setup consisted of a C18 reversed phase liquid chromatog-
raphy (RP-LC) system coupled online via electrospray ionization
(ESI) to a MS/MS. This general framework became the stan-
dardmethod for identifying pMHC. An increasing number of re-
ports have highlighted the inﬂuence of the applied fragmentation
methodology (e.g., CID, HCD, and EThcD) on the depth and fea-
tures of the identiﬁed immunopeptidome. In fact, MS/MS spec-
trum generation and acquisition is even more important in im-
munopeptidomics as compared to other sample types due to the
very diverse physical chemical properties of these endogenous
peptides.[25] Thanks to tremendous technological development in
the MS/MS ﬁeld over the last decade, large-scale MHC-class I
and MHC-class II immunopeptidome analyses have taken oﬀ in
recent years,[6,26,27] thus drastically increasing the availability of
immunopeptidome datasets.
3.1. LC-MS/MS Analysis—Compatible with the General MS
MIAPE Guidelines[28]
3.1.1. LC-MS/MS Metadata
Indicate the name of the manufacturer and model of the mass
spectrometer and chromatography system. Indicate the acquisi-
tionmethod (DDA, DIA, SRM) and fragmentationmethod (CID,
HCD, ETD, EThcD).
3.1.2. Trapping Column
If applicable, indicate the name of the manufacturer and model
of the trapping column and if packed in-house. Describe the sta-
tionary phase including the name of manufacturer for in-house
packed trapping columns. Indicate the length and inner diameter
of the trapping column.
3.1.3. Analytical Column
Indicate the name of the manufacturer and model of the analyti-
cal column and if packed in-house. Describe the stationary phase
including the name of manufacturer for in-house packed analyt-
ical columns. Indicate the length and inner diameter of the ana-
lytical column. For in-house packed columns, indicate the frit or
Arched-Tip used for packing.[29]
3.1.4. Mobile Phases and Gradient
Indicate the composition of themobile phases, the total run time,
ﬂow rate, and temperature of the LC. Describe the gradient in
terms of time and percentage of mobile phases.
3.1.5. Ion Source Type
Indicate the type of ion source (e.g., ESI, MALDI). List any mod-
iﬁcations made to the standard speciﬁcation. If the interface is
entirely custom-built, describe it or provide a reference if avail-
able. Indicate the manufacturing company and model name for
the ESI emitter; list any modiﬁcations made to the standard
speciﬁcation. If the emitter is entirely custom-built, describe it
brieﬂy or provide a reference if available. If the ion source is
MALDI, indicate the laser energy absorbing matrix in which
the sample is embedded (e.g., alpha-cyano-4-hydroxycinnamic
acid).
3.1.6. MS Acquisition Approach
Describe the instrument’s parameter settings and the acquisition
method. Importantly, a sizeable number of pMHC only occur
as singly charged species[26]; therefore, indicate the charge state
selection. Furthermore, indicate the mass ranges, the automatic
gain control (AGC) ion target values and maximal allowed injec-
tion times for full MS scan and MS/MS, the isolation window,
and resolution. Specify the acquisition sequence, for instance a
top-ﬁvemethodwith a cyclemade of one fullMS scan followed by
a precursor selection of the ﬁve most intense ions for fragmenta-
tion applying a dynamic exclusion window of 30 s. In the case of
SRM experiments, specify all transitions and detection windows.
4. Informatics and pMHC Identiﬁcation
Large-scale immunopeptidomics experiments create increas-
ing amounts of data, which makes it impractical or even
impossible to present all potential results within a typi-
cal manuscript. For example, post-translationally modiﬁed
pMHC (e.g., phosphorylations,[30] symmetric vs asymmetric
demethylation,[31] O-GlcNAc vs O-GalNAc[32]) may be directly
identiﬁed by enabling variable modiﬁcations in the database
searches. Therefore, all raw and processed data should be
submitted to a public proteomic or immunopeptidomic repos-
itory (e.g., the resources included in the ProteomeXchange
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Consortium [http://www.proteomexchange.org/], such as
PRIDE, MassIVE, jPOST, and iProX repositories,[33] or the
recently created SysteMHC Atlas immunopeptidomic data
repository [https://systemhcatlas.org/][34]) to enable better
collaborations among researchers and data reuse by third
parties, to advance the ﬁeld more eﬃciently. As discussed above,
immunopeptidomics experiments are carried out by applying
diﬀerent methods, using a variety of instrument types, and
employing diﬀerent computational analysis tools. Therefore,
accurate reporting of both experimental and computational
parameters is essential to improve interpretation, accessibility,
and reproducibility of immunopeptidomics data.
4.1. Informatics—Compatible with the MIAPE for Quantitative
MS[11] and MIAPE for MS Informatics[10] Guidelines
4.1.1. Informatics Metadata
Indicate if the identiﬁcation of pMHC has been performed using
a sequence based or a de novo approach. Indicate if a quantiﬁca-
tion analysis was performed. If applicable, indicate the method
used for assigning peptides to their corresponding MHC allo-
types, for example, using mono-allelic cell lines, clustering tools
(including version number), and aﬃnity prediction algorithms
(including name and version number), and if the list of reported
pMHC has been ﬁltered accordingly.
4.1.2. Raw Data Processing and Database Searches
Indicate all the speciﬁc parameters used in the identiﬁcation
analysis. Follow the speciﬁc MIAPE guidelines related to the
diﬀerent techniques (including DDA, SRM, spectral library
searches).[10,11] Indicate the version name and number of the tool
used for generating “peak list” ﬁles. Include parameters used
in the creation of this peak list (e.g., whether smoothing was
applied, any signal-to-noise criteria, whether charge states were
calculated or peaks de-isotoped).
Indicate the name and version number of the search engine
tool used. In case of multiple tools, indicate the order in which
they were used and how the results were combined. Include the
parameters used for the database search (e.g., precursor-ionmass
tolerance, fragment-ion mass tolerance, as well as dynamic and
static modiﬁcations allowed). If possible, provide the conﬁgura-
tion ﬁle for the search tool.
Indicate the name and version of the reference sequence
database including the number of entries within the database. In
case of custom compiled databases, submission of the respective
.fasta ﬁles of the target and decoy databases to a public repository
is encouraged.
Indicate retention time and precursor mass, charge and mass
error observed, and identiﬁcation score(s). Indicate the decoy
strategy applied to estimate false discovery rate (FDR), and if
the FDR has been applied at the peptide spectrum match or
at the peptide level. Indicate the thresholds and values spe-
ciﬁc to judging certainty of identiﬁcations and any related ad-
ditional statistical analyses. If possible, indicate the number of
peptide-spectrummatches, score diﬀerence to the second best ﬁt,
any associated statistical information obtained for the conducted
searches (e.g., posterior error probability [PEP][35] and q values
of the peptides), and the number of observed fragment ions.
If possible, both target and decoy peptide sequences should be
deposited.
4.1.3. Identiﬁcation and Mapping of pMHC to Proteins
For each identiﬁed pMHC, provide the accession number of
the parent protein(s) and position within the protein. Indicate
whether the peptide mappings to the proteins included in the
search database are unique/unambiguous or not. In case of
ambiguous mappings, all potential proteins (protein groups)
mapped should be reported. As identical peptide sequences can
be included in multiple unique protein sequences due to biologi-
cal variation such as single amino acid variants, alternative splice
forms, and homologs, all potential source proteins should be
reported.
4.1.4. Post-translationally Modiﬁed pMHC
For each post-translationally modiﬁed pMHC, indicate the mod-
iﬁcation name and site in the peptide sequence and the number
of modiﬁcations. When ambiguity with regard to the modiﬁca-
tion site cannot be resolved, cite whether speciﬁc software has
been used or not. If speciﬁc software has been used, the name,
version, and all corresponding scores should be indicated. The
ambiguity must be explicitly shown.
If possible, provide evidence for assigning a speciﬁc mod-
iﬁcation or variant peptide sequence over another in case of
isobaric modiﬁcations or diﬀerent isobaric amino acid combi-
nations (e.g., acetylation vs trimethylation, phosphorylation vs
sulfation, symmetric vs asymmetric dimethylation, O-GlcNAc vs
O-GalNAc etc.).
4.1.5. Quantiﬁcation of pMHC
Indicate all the speciﬁc parameters used in the quantiﬁcation
analysis. Follow the speciﬁc MIAPE guidelines related to the dif-
ferent quantiﬁcation techniques (including labeled, e.g., SILAC
and iTRAQ, label-free, or absolute quantiﬁcation).[11]
Indicate the signal extraction method and for each peptide the
MS intensity per measured sample (mean and standard devia-
tion) or per LC run. Specify howMS intensities were normalized.
Indicate any data manipulation such as related to systematic
error eﬀects, interference from overlapping precursor ions, in-
complete isotope labeling, correction for pipetting error, imputa-
tion of missing values, rejection of outliers, and the categorical
exclusion of data by thresholds.
4.1.6. Data Availability
Data should be made openly available to the scientiﬁc com-
munity. It is encouraged that data is submitted to one public
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repository, following the requirements established by the Pro-
teomeXchange Consortium.[33] Data submissions must then in-
clude at least: the metadata information described in Section
2.1.1, raw data (MS data coming from the mass spectrometer),
and processed results, including the output of the analysis (ide-
ally in an open standard format if possible, e.g., mzIdentML,
mzTab). In addition, it is encouraged that peak list ﬁles are al-
ways included (in a suitable open format, e.g., mzXML, mzML,
mgf, etc.), together with any other data type that can help to im-
prove experimental reproducibility.
If there are selected peptides of key interest (e.g., virus-
derived), the annotated MS/MS spectra of the key peptides
should be provided as supplemental material accompanying the
manuscript. If this is not possible, ensure that the submission to
a public repository enables this functionality (the so-called “com-
plete” submissions, which use PSI standard formats).
4.1.7. Software Availability
If possible provide any “home-made” tailored scripts (e.g., in a
source code repository such as GitHub, Bitbucket, among oth-
ers), that were used for data manipulation, between the diﬀerent
analysis steps.
5. Conclusion
The main objective of the MIAIPE guidelines is to harmonize
the way immunopeptidomics studies are reported in scientiﬁc
manuscripts and deposited in public repositories. This commu-
nity eﬀort wishes to facilitate transparent experimental reporting,
data sharing, and distribution and reuse of datasets and by that
to advance best practice in this emerging ﬁeld. The broadness
of the required MIAIPE description matches to similar guide-
lines from other disciplines where such guidelines are more ma-
ture and therefore well implemented and acknowledged.[13,36] We
anticipate that these guidelines will evolve in parallel with the
ﬁeld. We envision that widespread compliance with the MIAIPE
guidelines will standardize the reported content of MS-related
immunopeptidomics studies and will increase the general value
of the conducted research for the advantage of the growing im-
munopeptidomics scientiﬁc community.
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